Labels and claims
Cosmetic vs. Drug Claims: Why Product Wording Matters
Two jars can contain similar creams and be regulated differently because of how they are presented. In U.S. law, intended use is drawn from the labeling, the advertising, and the circumstances of sale. A brand’s internal category does not override a presentation that implies treatment of disease or a change to the structure or function of the body.
The Food and Drug Administration’s clearest short explanation is “Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?)”. The statutory definitions live in the Federal Food, Drug, and Cosmetic Act. FDA also summarizes the cosmetic side in Cosmetics Laws & Regulations.
The two definitions, in plain language
A cosmetic, as FDA describes it, is an article intended to be applied to the body for cleansing, beautifying, promoting attractiveness, or altering the appearance. A drug includes articles intended to diagnose, cure, mitigate, treat, or prevent disease, and articles intended to affect the structure or any function of the body. A product can be both when it has both kinds of intended use. FDA’s own illustration is an antidandruff shampoo: it cleanses and it treats. The drug purpose does not disappear because the product also sits in a shower.
That is why presentation matters more than the aisle. Appearance, comfort, and cleansing sit in a different conversation from condition-oriented claims, therapeutic implications, and promises to change how the body works. Getting the positioning wrong has a business cost: a marketplace can pull the listing, a retailer can refuse the item, and a campaign built for a cosmetic launch can stall while the category is sorted out.
Category, context, and the whole product
The question is what a shopper is being offered, not which adjective a copywriter prefers. Context, claims, imagery, category, substantiation, and the rest of the marketing all affect that reading. A face cream positioned only as appearance care is a different story from one positioned as a response to a medical condition, or as a product that changes skin structure. FDA has long treated some of those positions under drug rules, including acne products. That history is public: Rulemaking History for OTC Acne Drug Products.
Sunscreen is a concrete case of a product people meet in the cosmetic aisle that FDA regulates as a drug. FDA’s consumer page is Sunscreen: How to Help Protect Your Skin from the Sun. Sun-protection positioning on a moisturizer is a category choice, not a cosmetic flourish. A brand that wants only a cosmetic moisturizer should not borrow that position to sound more serious.
Listings, imagery, and ads count
Intended use is not limited to the carton. A marketplace title, a bullet, an infographic, and a creator script tell the buyer what the product is for. If the package talks about daily care and the listing presents a therapeutic use, the listing is part of the product story. How condition-oriented marketing changes interpretation is covered in when cosmetic marketing changes how a product is interpreted.
Images do the same work. Clinical-looking diagrams, medical symbols, or before-and-after images of a condition can supply a meaning the sentence avoided. Review the frame and the caption together with the words.
The Federal Trade Commission still expects the claim, whatever the category, to have support. Health-related advertising is discussed in the Health Products Compliance Guidance. Strong proof language on top of a cosmetic or drug claim is a separate evidence question, covered in what “clinically proven” means.
What does not settle the category
Several common comforts do not decide how the product will be read:
- An INCI name identifies an ingredient. It does not make a therapeutic implication cosmetic.
- MoCRA facility registration and product listing are cosmetic obligations. They are not FDA approval of claims. FDA’s overview: Modernization of Cosmetics Regulation Act of 2022.
- A supplier irritation test is not a drug approval and not evidence for a therapeutic claim.
- Calling the product “cosmeceutical” is a marketing word. It is not a third legal category that sits between cosmetic and drug.
- A model asked to write polished cosmetic copy can still shift the positioning. Review the output. See AI-generated product descriptions.
When a brand actually intends a drug use, the path is to meet the drug or OTC requirements that apply, including active-ingredient and labeling conditions. Softening the tone of a cosmetic file does not replace that work. The assessment depends on the specific product, the active ingredient, and the conditions that apply.
Review the product as one story
Packaging, marketplace, and creator teams often edit on different days. The shopper sees one product. So does a regulator. The useful question is what the whole presentation says the product is for: appearance and cleansing, or a therapeutic or structure-or-function role. Overstated performance claims, comparisons, and absolute “free from” lines can still mislead when the category itself is cosmetic.
Creator posts belong in that same picture. A brief that asks for a treatment outcome, or for a regulated benefit without naming it, is still the brand’s claim. Disclosures are covered separately in FTC influencer disclosure basics.
What deserves attention
- Category-positioning issues, where the public story and the planned regulatory category no longer match.
- Therapeutic implications and condition-oriented claims across packaging, listings, imagery, and creator briefs.
- Context that images and titles add even when the back panel stays mild.
- Reliance on an INCI list, a MoCRA listing, or the word “cosmeceutical” to carry the positioning.
- Evidence-sensitive claims, including strong proof language, that still need support inside the chosen category.